HIV/AIDS drug development and treatment
HIV/AIDS drug development and treatment is a research topic within Infectious Diseases. Science Explorer counts 46k research works in it since 1950. 18.7% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the efficacy and safety of antiretroviral therapy for HIV infection, including the development of drug resistance, the use of integrase inhibitors and reverse transcriptase inhibitors, and the adverse effects such as hepatotoxicity and renal toxicity. It also explores the use of nucleoside analogues for treating viral diseases.
- Antiretroviral Therapy
- HIV Infection
- Drug Resistance
- Integrase Inhibitors
- Nucleoside Analogues
- Adverse Effects
- Viral Diseases
- Reverse Transcriptase Inhibitors
- Hepatotoxicity
- Renal Toxicity
- Research works
- 46k fractional, since 1950
- In the world top 10%
- 8.6k per year above
- Top-10% rate
- 18.7% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- -15% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead HIV/AIDS drug development and treatment research?
By volume, the United States and China publish the most (1.2k and 508 works in 2022–2025).
By volume, 2022–2025
- 1 United States 1.2k works
- 2 China 508 works
- 3 India 304 works
- 4 Italy 179 works
- 5 United Kingdom 176 works
- 6 France 154 works
- 7 South Africa 148 works
- 8 Spain 147 works
- 9 Japan 101 works
- 10 Brazil 98 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead HIV/AIDS drug development and treatment research?
By volume in 2022–2025, University of North Carolina at Chapel Hill publishes the most HIV/AIDS drug development and treatment research, followed by Gilead Sciences (United States) and Johns Hopkins University.
By volume, 2022–2025
- 1 University of North Carolina at Chapel HillUnited States 71 works
- 2 Gilead Sciences (United States)United States 27 works
- 3 Johns Hopkins UniversityUnited States 25 works
- 4 University of the WitwatersrandSouth Africa 23 works
- 5 University of California, San FranciscoUnited States 23 works
- 6 University of WashingtonUnited States 20 works
- 7 University of Cape TownSouth Africa 19 works
- 8 Emory UniversityUnited States 19 works
- 9 Harvard UniversityUnited States 18 works
- 10 Johns Hopkins MedicineUnited States 17 works
Who are the leading researchers in HIV/AIDS drug development and treatment?
The most-cited researchers publishing on HIV/AIDS drug development and treatment include Arthur J. Olson and Kebede Deribe.
- 1 Arthur J. Olson United States 5k citations
- 2 Kebede Deribe Ethiopia 4.5k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is HIV/AIDS drug development and treatment research done?
The largest centres of HIV/AIDS drug development and treatment research in 2022–2025 are Beijing (China), London (United Kingdom), Paris (France) and Chapel Hill (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Foster City, Kampala and Cape Town.
Largest cities, 2022–2025
- 1 Beijing China 91 works
- 2 London United Kingdom 85 works
- 3 Paris France 74 works
- 4 Chapel Hill United States 73 works
- 5 Baltimore United States 55 works
- 6 Madrid Spain 55 works
- 7 Shanghai China 49 works
- 8 New York United States 48 works
- 9 Boston United States 48 works
- 10 Atlanta United States 47 works
Where it is the local speciality
- Foster CityUS · 27.7 works211×
- KampalaUG · 39.6 works21×
- Cape TownZA · 26.7 works15×
Location quotient: how much more of its research is in HIV/AIDS drug development and treatment than the world average.
Where is the best place to study HIV/AIDS drug development and treatment?
Among universities, judged by research, University of Gondar, University of the Witwatersrand and University of Cape Town score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | University of GondarEthiopia | 60.8 | 24.6% | 12.7× | 8 | +178.0% |
| 2 | University of the WitwatersrandSouth Africa | 58.0 | 20.0% | 13.0× | 23 | +12.3% |
| 3 | University of Cape TownSouth Africa | 56.5 | 19.5% | 14.1× | 20 | +1.7% |
| 4 | University of KwaZulu-NatalSouth Africa | 54.2 | 20.7% | 9.1× | 14 | +60.3% |
| 5 | Makerere UniversityUganda | 51.9 | 18.6% | 18.8× | 14 | -20.8% |
| 6 | University of North Carolina at Chapel HillUnited States | 50.4 | 5.2% | 9.9× | 72 | +34.4% |
| 7 | University of California, San FranciscoUnited States | 49.6 | 19.8% | 8.4× | 23 | -16.1% |
| 8 | University of LiverpoolUnited Kingdom | 44.8 | 26.4% | 5.3× | 11 | -17.5% |
| 9 | Emory UniversityUnited States | 41.1 | 18.0% | 6.5× | 19 | +3.1% |
| 10 | Johns Hopkins UniversityUnited States | 41.0 | 18.0% | 5.5× | 25 | -14.2% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is HIV/AIDS drug development and treatment research growing?
Output in 2018–2022 was 15% lower than in 2013–2017, peaking in 2014. The fastest-growing topics are HIV/AIDS drug development and treatment.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.